An AI-Built Lung Drug May Have Also Reversed 3 to 4 Years of Aging | Edition 341

In partnership with

Wispr Flow turns your voice into clean, ready-to-send writing — speak naturally, it strips the filler and fixes the punctuation. I've used it daily since February 2026 to build this newsletter. Read the full review →

An AI-designed lung drug may have also reversed aging. Here’s what six AI models actually found, and what a Nobel laureate says it doesn’t prove yet.

Last year, Insilico Medicine tested a new pill, rentosertib, for idiopathic pulmonary fibrosis, a fatal lung disease with no cure. It worked well enough to move into Phase III trials.

Last month, the same 42 patients’ blood samples got a second look, and that’s the real news: six independently built AI “aging clock” models, none sharing data or training with each other, all agreed patients on the drug showed a lower predicted biological age than patients on placebo.

Rentosertib isn’t a repurposed old drug like metformin or rapamycin, the usual candidates in anti-aging research. It’s the first drug where AI both found the biological target (a protein called TNIK, tied to six separate “hallmarks of aging”) and designed the molecule itself, from scratch. That took about 18 months. Traditional drug discovery usually takes years for that step alone.

The strongest age-reversal signal showed up at week 4, in patients taking 30 mg twice daily, which was not the dose that helped lungs the most. Several of the six clocks estimated roughly 3 to 4 years of biological age reversal; one estimated close to 6. Placebo patients barely moved. Researchers point to that mismatch, with the best lung result and the best aging result coming from different doses, as evidence the aging effect isn’t just a side effect of healthier lungs.

The next wave of millionaires will be people who figured out how to make AI work for them.

The window to get ahead is still open. But not for long.

Here are 200+ proven ways to make money with AI in 2026.

Sign up for Superhuman AI, the free daily newsletter read by 1M+ professionals, and get instant access to all 200+ ways to profit from AI this year.

Claim your free list

Michael Levitt, the 2013 Nobel laureate in Chemistry who reviewed the study, said it plainly: this trial can’t yet separate “aging more slowly” from “the lungs got better, and that shows up in blood work.” He wants to see the same drug tested in healthy people with no lung disease, a study that hasn’t happened.

Worth weighing that against the headline: 42 people, all already sick, average age 67. The “aging clocks” measure blood proteins linked to age, not actual lifespan or organ health. And the study’s lead author is Insilico’s own co-founder and co-CEO, Alex Zhavoronkov. None of that makes the finding fake. It means “reverses aging” is carrying more weight than one small, company-run study can support on its own.

The bigger deal might be the template: folding aging measurements into an ordinary disease trial, at no extra cost, instead of requiring a separate decades-long study. If regulators warm to that approach, it could speed up how the whole anti-aging drug field gets tested, well beyond this one drug. Insilico is also newly profitable, posting about $106 million in first-half 2026 revenue (up 287% from a year earlier) and roughly $7.3 billion in announced deal value this year.

Rentosertib is now in Phase III for the lung disease in China. That’s the approval path that matters first. The aging story rides along as a genuinely open question, not a settled one.

It’s your always-on revenue engine: agents and workflows build pipeline, chase every buying signal, and move deals forward alongside your team.

Teams like Parallel, Turbopuffer, and Wordsmith build on Attio. Are you one of them?

Try Attio now

— Jerry
AI Super Simplified